TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Serological confirmation of chronic infection by anti-hepatitis C virus (HCV) assay~* HCV ribonucleic acid (RNA) positive~* CHC with normal transaminases~* Compensated liver disease~* Non-pregnant and willing to use two contraceptive methods (if fertile)~* At least 4 weeks of prior treatment with peginterferon alfa-2a and ribavirin~Exclusion Criteria:~* Pregnant or lactating women~* Co-infection with hepatitis A or B, or human immunodeficiency virus (HIV)~* History of seizures or depression~* History of autoimmune disease, severe heart or lung disease, or renal failure with reduced creatinine clearance~* Uncontrolled thyroid disease~* Severe retinopathy~* Leukopenia or thrombocytopenia~* Bleeding esophageal varices or other evidence of hepatic decompensation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Hepatitis C Participants (Type: None): Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration~Exclusion Criteria:~* Non-consenting~* Hypersensitivity to the active substance or to any of the excipients~* galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epilepsy (Type: None): None
- Neuropathic Pain (Type: None): None
- Fibromyalgia (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes for more than 12 months~* Currently treated with glucose lowering tablets or insulin~* HbA1c: 7.0-12.0%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIIB Subcutaneous Abatacept Monotherapy Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Rheumatoid Arthritis~* Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog scale~* Discontinue all Biologics and Disease-modifying antirheumatic drugs (DMARDS) except for methotrexate~Exclusion Criteria:~* Received treatment with rituximab~* Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort (Type: EXPERIMENTAL): In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
- SC Abatacept Monotherapy Cohort (Type: EXPERIMENTAL): In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically stable Type 2 Diabetes Mellitus~* Females without childbearing potential~* Body mass index (BMI) \>= 18.5 kg/m2 and \<= 39.9 kg/m2~* Hemoglobin A1c levels \>= 6.5% and \<= 10%~* Fasting blood glucose levels \>= 140 mg/dL and \<= 270 mg/dL~* Systolic blood pressure \>= 95 mmHg and \<= 160 mmHg, and diastolic blood pressure \>= 50 mmHg and \<= 100 mmHg, and pulse rate \>= 50 bpm~* Patients who have not been administered anti-diabetic medication within 2 weeks Prior to dosing~* Medicines if necessary for Hypertension or Dyslipidemia should be administered with stable dosage at least 3 months~* Treatment with diet and exercise should be unchanged for more than 3 months~Exclusion Criteria:~* Type 1 Diabetes Mellitus or Secondary Diabetic Mellitus~* History of diabetic complications which need treatment~* Treatment with insulin, thiazolidinediones, thiazide diuretics、beta blockers or systemic steroids within 3 months prior to informed consent~* Serum creatinine \> upper limit of the normal range~* Patients with significant complications

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TA-7284 (Type: EXPERIMENTAL): None
- Placebo of TA-7284 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Part I: Subjects between 18 and 45 years old (inclusive), with a body mass index (BMI) of 18 to 30 kg/m² (exclusive) and in a good health.~* Part II: Patients 18 years old and older and having at least one brain lesion with a disruption of the blood brain barrier (BBB) and/or with abnormal vascularity in the brain. This/these lesion(s) must have been detected by previous imaging evaluation (Computed Tomography or MRI).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part I (Phase I) (Type: EXPERIMENTAL): In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
- Part II (Phase IIA) (Type: EXPERIMENTAL): In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. - Having voluntarily given informed consent before performing any test that is not part of~   routine care of patients.~2. - Age greater than or equal to 65.~3. - Morphological diagnosis of non-promyelocytic AML according to the WHO criteria.~4. - Newly diagnosed AML.~5. - ECOG performance status \<4.~6. - Ability and willingness to comply with the schedule of study visits.~Exclusion Criteria:~1. - Genetic diagnosis of acute promyelocytic leukemia.~2. - Patients with AML secondary to myelodysplastic syndrome (MDS) or chronic myeloproloferative syndrome who have been previously treated with antileukemic agents~   (hypomethylating or standard chemotherapy). Treatment with hydroxyurea prior to randomization is allowed.~3. - Serum creatinine ≥ 250 mmol / l (≥ 2.5 mg/dL) (unless attributed to AML).~4. - Bilirubin, alkaline phosphatase or ALT \> 5 times the value of the upper limit of normal (unless attributed to AML) .~5. - Presence of an active and/or non controlled pathology different to AML which is severe and life-threatening, that in the investigator's opinion, prevents the subject participation in the study.~6. - Other active concomitant malignancy or whose remission is less than one year from the screening day (except carcinoma in situ).~7. - Presence of any psychiatric illness or medical condition that, in the investigator's opinion, prevents the subject participation in the study.~8. - Life expectancy less than X months.~9. - Inability of the patient or his legal representative to understand and voluntarily sign the informed consent form.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fludarabine cytarabine (Type: ACTIVE_COMPARATOR): Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis\> 25 x 109/l), followed by:~* Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR~* Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).~Treatment cycles every 28 days
- Azacitidine (Type: EXPERIMENTAL): Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parent or legal guardian agrees to have infant participate by giving written informed consent~Exclusion Criteria:~* History of congenital abdominal disorders, prior rotavirus gastroenteritis, chronic diarrhea, failure to thrive, or abdominal surgery~* History of intussusception~* Known or suspected impairment of immunological function, including Severe~Combined Immunodeficiency (SCID)~* Prior administration of any rotavirus vaccine~* Clinical evidence of active gastrointestinal illness, with the exception of well-controlled gastroesophageal reflux disease (GERD)~* Receipt of 1) systemic corticosteroids (≥ 2mg/kg total daily dose of prednisone or equivalent) for 14 consecutive days or more since birth, or 2) systemic corticosteroids ≥ 2mg/kg/dose within 7 days prior to the administration of the first dose of study vaccine. Participant using non-systemic corticosteroids will be eligible for vaccination.~* Residing in a household with an immunocompromised person~* Prior receipt of a blood transfusion or blood products, including immunoglobulins~* Participation in another interventional study within 14 days prior to the first study vaccination or expected anytime during the study~* Receipt of investigational inactivated vaccines within 14 days or investigational live vaccines within 28 days prior to the first study vaccination or expected anytime during the study

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RotaTeq™ Experimental Formulation (Type: EXPERIMENTAL): Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
- RotaTeq™ Existing Formulation (Type: ACTIVE_COMPARATOR): Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Sedation in Children With Respiratory Morbidities

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children up to the age of 16 years with at least 3 characteristics of respiratory morbidities~Exclusion Criteria:~* Children who had an American Society of Anaesthesiologists (ASA) physical status classification IV~* Documented pre-existing cardiac conduction abnormalities~* Renal impairment

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signs and symptoms of pneumonia including at least 2 of the following: fever, cough, chest pain, shortness of breath, physical examination showing lung tissue has become airless and of solid consistency, white blood cell count \>15,000/uL or \<5000/uL (normal range is approximately from 3800/uL to 9800/uL)~* Chest x-ray showing evidence of lung infection~* Production of sputum (not an absolute requirement for enrollment~* however, all reasonable attempts to obtain a sputum specimen should be made~* Parental consent to participate in the study~Exclusion Criteria:~* Patients who have used antibiotics that affect the whole body for more than 24 hours immediately before the start of the study~* Requirement of antibiotic therapy that affects the whole body, other than study drug(s)~* Suspected infection with a bacteria known to be resistant to any of the study drugs~* Signs and symptoms of infection with a bacteria that affects the central nervous system~* History of a previous sensitivity or serious adverse reaction to any antibiotic similar to those used in this study~* History of cystic fibrosis~* Abnormal kidney function, as determined by blood test (serum creatinine)~* History or presence of joint disease or disease of the tissues surrounding joints, or any other signs or symptoms in muscles or bones that may make it difficult to evaluate any future complaints concernng muscles or bones~* Hospitalization or residence in a long-term care facility for 14 or more days before the beginning of pneumonia symptoms~* Infection acquired in a hospital~* Poorly controlled seizure disorder or at significant risk for seizures~* Unstable psychiatric disorder~* Known or highly suspected to be infected tuberculosis~* Known HIV (human immunodeficiency virus) infection requiring treatment to prevent PCP (pneumocystis carinii pneumonia~* a type of pneumonia that mainly affects those with compromised immune systems)~* Persistent use of corticosteroids

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of bipolar 1 disorder, currently experiencing a mixed or manic episode or stable~* Two or more bipolar mood episodes in the last 2 years excluding current episode~* Negative pregnancy test~Exclusion Criteria:~* History of \> than 4 mood episodes a year during the last two years~* patients experiencing a depressive episode~* History of antisocial or borderline personality illness~* Has unstable or serious general medical illness~* Has received medications disallowed by study criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
- 002 (Type: PLACEBO_COMPARATOR): Placebo Matching placebo intramuscular (IM) injection every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.~* Severity of psoriasis disease meeting all of the following three criteria:~Psoriasis Area and Severity Index (PASI) score of 12 or greater, Investigator's Global Assessment (IGA) score of 3 or greater, Total body surface area (BSA) affected of 10% or greater.~-Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.~Exclusion criteria:~* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).~* Current drug-induced psoriasis.~* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.~* Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.~* Hematological abnormalities.~* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.~* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.~* Pregnant or nursing (lactating) women. Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- secukinumab 150 mg (Type: EXPERIMENTAL): Drug
- secukinumab 300 mg (Type: EXPERIMENTAL): Drug
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female and at least 18 years of age~* Female patients must be of either:~  * Non-childbearing potential, post-menopausal~ * Childbearing potential, provided there are negative serum and urine pregnancy test results prior to study treatment, to rule out pregnancy~Exclusion Criteria:~* Cosmetic or therapeutic procedures within 2 weeks and 2cm of the selected treatment area~* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks~* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEP005 (Ingenol Mebutate) gel (Type: EXPERIMENTAL): None
- Vehicle gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete